Coya Therapeutics (COYA) vs enGene Therapeutics (ENGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Coya Therapeutics (COYA) has outperformed enGene Therapeutics (ENGN) over the past year, losing 20.9% versus a loss of 76.0%. enGene Therapeutics is the larger company by market cap ($119.3 million vs $117.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | ENGN |
|---|---|---|
| Share price | $4.99 | $1.78 |
| Market cap | $117.05M | $119.29M |
| 1-day change | +1.63% | +2.01% |
| YTD return | -13.97% | -80.29% |
| 1-year return | -20.92% | -75.98% |
| EPS (TTM) | $-1.07 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $12.25 |
| 52-week low | $3.71 | $1.40 |
| Distance from 52-week high | -35.61% | -85.47% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +204.81% | +84.83% |
| Average volume | 158.05K | 748.14K |
| Shares outstanding | 23.46M | 67.02M |
| Employees | 8 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COYA has outperformed ENGN by 55.1 percentage points over the past year.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
COYA vs ENGN FAQ
Which is bigger, Coya Therapeutics or enGene Therapeutics?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $119.29M compared with $117.05M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, COYA or ENGN?
COYA returned -20.92% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and enGene Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Coya Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for enGene Therapeutics.